Paris Maryline, Tourrel-Cuzin Cécile, Plachot Cédric, Ktorza Alain
Laboratoire de Physiopathologie de la Nutrition, Universite Paris 7, Paris, France.
Exp Diabesity Res. 2004 Apr-Jun;5(2):111-21. doi: 10.1080/15438600490455079.
Beta-cell neogenesis triggers the generation of new beta-cells from precursor cells. Neogenesis from duct epithelium is the most currently described and the best documented process of differentiation of precursor cells into beta-cells. It is contributes not only to beta-cell mass expansion during fetal and nonatal life but it is also involved in the maintenance of the beta-cell mass in adults. It is also required for the increase in beta-cell mass in situations of increase insulin demand (obesity, pregnancy). A large number of factors controlling the differentiation of beta-cells has been identified. They are classified into the following main categories: growth factors, cytokine and inflammatory factors, and hormones such as PTHrP and GLP-1. The fact that intestinal incretin hormone GLP-1 exerts a major trophic role on pancreatic beta-cells provides insights into the possibility to pharmacologically stimulate beta-cell neogenesis. This could have important implications for the of treatment of type 1 and type 2 diabetes. Transdifferentiation, that is, the differentiation of already differentiated cells into beta-cells, remains controversial. However, more and more studies support this concept. The cells, which can potentially "transdifferentiate" into beta-cells, can belong to the pancreas (acinar cells) and even islets, or originate from extra-pancreatic tissues such as the liver. Neogenesis from intra-islet precursors also have been proposed and subpopulations of cell precursors inside islets have been described by some authors. Nestin positive cells, which have been considered as the main candidates, appear rather as progenitors of endothelial cells rather than beta-cells and contribute to angiogenesis rather than neogenesis. To take advantage of the different differentiation processes may be a direction for future cellular therapies. Ultimately, a better understanding of the molecular mechanisms involved in beta-cell neogenesis will allow us to use any type of differentiated and/or undifferentiated cells as a source of potential cell precursors.
β细胞新生可触发前体细胞生成新的β细胞。导管上皮细胞的新生是目前描述最多且记录最完善的前体细胞分化为β细胞的过程。它不仅有助于胎儿和新生儿期β细胞量的增加,还参与维持成年期的β细胞量。在胰岛素需求增加的情况下(肥胖、妊娠),β细胞量的增加也需要它。已鉴定出大量控制β细胞分化的因素。它们主要分为以下几类:生长因子、细胞因子和炎症因子,以及诸如甲状旁腺激素相关蛋白(PTHrP)和胰高血糖素样肽-1(GLP-1)等激素。肠道促胰岛素激素GLP-1对胰腺β细胞发挥主要营养作用这一事实,为通过药物刺激β细胞新生的可能性提供了思路。这可能对1型和2型糖尿病的治疗具有重要意义。转分化,即已分化细胞分化为β细胞,仍存在争议。然而,越来越多的研究支持这一概念。可能“转分化”为β细胞的细胞,可来自胰腺(腺泡细胞)甚至胰岛,或起源于肝等胰腺外组织。也有人提出胰岛内前体细胞的新生,一些作者描述了胰岛内细胞前体亚群。巢蛋白阳性细胞一直被视为主要候选细胞,但它们似乎更像是内皮细胞的祖细胞而非β细胞,并且对血管生成而非新生有贡献。利用不同的分化过程可能是未来细胞治疗的一个方向。最终,更好地理解β细胞新生所涉及的分子机制,将使我们能够将任何类型的分化和/或未分化细胞用作潜在细胞前体的来源。